Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T Cell Immunotherapy for Lung Cancer and Solid Tumors
NCT03778814Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2018
- Primary completion
- Dec 2029
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KK-LC-1 TCR-T cells in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Number of Patients with Dose Limiting Toxicity at 3 months. Started Dec 2018; status: recruiting.
02
Drugs
KK-LC-1 TCR-T cells
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT03778814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778814.